Developer docs
API playgroundTry for free, no card

Search company profiles

Yangzijiang Pharmaceutical

Full company profile

uuid002m2q8

Namestring
Yangzijiang Pharmaceutical
Legal namestring
扬子江药业集团北京海燕药业有限公司
Websiteurl
bjhaiyan.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Beijing Haiyan Pharmaceutical Co., Ltd. (扬子江药业集团北京海燕药业有限公司) is a wholly-owned subsidiary of Yangzijiang Pharmaceutical Group, established in February 2004 and headquartered on a ~99 mu (~65,979 sqm) campus in Beijing's Zhongguancun Life Science Park (Changping District). The company operates as Yangzijiang Group's only integrated R&D, manufacturing, and market expansion hub in northern China, executing a dual TCM-chemical drug ("双药并举") strategy spanning respiratory, cardiovascular, central nervous system, endocrine, and anti-infective therapeutic areas. Core marketed products include Suhuang Zhike Capsule (Suhuang Cough Capsule, the only TCM recommended in Western Medicine Cough Guidelines, entered the 2020 Chinese Pharmacopoeia), Kesu Irbesartan Tablets (antihypertensive, passed consistency evaluation), Benoic Rizatriptan Tablets (acute migraine), and Monika Racecadotril Tablets (pediatric acute diarrhea), supported by a Drug Research Institute developing additional candidates such as Xinsu ultrasound contrast agent and fat emulsion injection technology.

The subsidiary's manufacturing backbone rests on advanced pharmaceutical technology platforms, including the group's Longfentan (龙凤堂) Smart Factory for full-process digital-intelligent TCM manufacturing (automatic feeding, robot dispensing, MES systems), proprietary volatile/non-volatile fingerprint analysis methods for Suhuang (a domestic first in multi-component TCM quality control), and Box-Behnken response surface optimization for fat emulsion physical stability. Production is supported vertically through 33 standardized TCM planting bases covering 100,000 mu across China, with a dedicated Gansu base of 15,000+ mu established since 2014 and a new Longfentan industrial base launched in Gansu in 2023.

Commercially, Beijing Haiyan generates revenue through prescription pharmaceutical sales distributed exclusively via Yangzijiang Group's nationwide sales network into Chinese hospitals, pharmacies, and medical institutions, with 66 group-level products now selected in China's national volume-based procurement (集中采购) as of 2025. Pricing is governed by national reimbursement (NRDL) and centralized procurement mechanisms rather than market pricing. The group is also expanding into the "大健康" (large health) consumer segment via Huangqi Sports Drinks, Huangqi Coffee, Lanqin Throat Candy, and Yulan Skincare. Reported financials include 2018 subsidiary revenue of 991.598 million RMB with 158.68 million RMB net profit, cumulative 2004–2018 revenue of 7.418 billion RMB, and group-level 2025 international revenue growth of 425% YoY with large health segment growth of 239% YoY.

Short descriptiontext

Beijing Haiyan Pharmaceutical is the northern China R&D-manufacturing subsidiary of Yangzijiang Pharmaceutical Group, developing and producing TCM and chemical drugs (notably Suhuang Cough Capsules, Kesu Irbesartan) for distribution through the group's national hospital sales network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersChangping, China
HQ citystring
Changping
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, traditional Chinese medicine, generic drug production, respiratory therapeutics, cardiovascular medications
Industry4 codes
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Manufacturing and Sales
TypeOne Time License
Description

Beijing Haiyan manufactures and sells prescription pharmaceutical products including Suhuang Cough Capsules (呼吸系统), Kesu Irbesartan Tablets (心血管), Xiaoxuan Kaduoqu Tablets (儿科), and Benoic Lizatriptan Tablets (神经系统). Products are distributed through Yangzijiang Group's nationwide sales network. Revenue primarily comes from product sales to hospitals, pharmacies, and medical institutions across China.

bjhaiyan.com
2Health Consumer Products (Large Health / 大健康)
TypeOne Time License
Description

Yangzijiang Group is expanding into health consumer products including Huangqi Sports Drinks, Huangqi Coffee, Lanqin Throat Candies, and Youlan Skincare products, targeting the consumer health and wellness market segment.

bjhaiyan.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription pharmaceutical products distributed through institutional channels — pricing governed by national medical insurance and centralized procurement systems.
ModelOtherBilling cadenceOther
Notes

Products are sold through hospitals, pharmacies, and medical institutions via the Yangzijiang Group's national distribution network. Pricing is subject to national drug price negotiation, national reimbursement drug list (NRDL), and volume-based procurement (集中采购) programs.

bjhaiyan.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Beijing Haiyan Pharmaceutical is the northern China R&D-manufacturing-sales subsidiary of Yangzijiang Pharmaceutical Group, producing prescription pharmaceuticals across respiratory, cardiovascular, central nervous system, endocrine, and anti-infective therapeutic areas. The company combines traditional Chinese medicine (TCM) and chemical drug production, with flagship product Suhuang Zhike Capsule (TCM cough/asthma treatment) and core chemical drugs including Irbesartan Tablets, Rizatriptan Benzoate Tablets, and Racecadotril Tablets. Products are distributed through the parent group's nationwide sales network to hospitals, pharmacies, and medical institutions across China.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Suhuang Cough Capsule clinical total effective rate: 87%+
+5 more records
Product overview1 text field

Yangzijiang Pharmaceutical Group is a comprehensive pharmaceutical company with Beijing Haiyan Pharmaceutical as its northern R&D and production subsidiary. The company operates a dual strategy of traditional Chinese medicine and chemical drugs (中药、化药"双药并举"), with respiratory and cardiovascular systems as key therapeutic areas. Core products include Suhuang Zhike Capsule (entered 2020 Chinese Pharmacopoeia), Ke Su (Irbesartan Tablets), Hao Su (Rizatriptan), and Monika (Racecadotril). The company also develops health products under brands including Longfengtang, Lanqin, and Yulan, encompassing functional beverages like Huangqi Sports Drink, throat care products, and skincare. The portfolio spans from patented TCM formulas to generic chemical drugs, supported by drug research institutes conducting research across antiviral, nervous system, cardiovascular, endocrine, and respiratory areas.

Product and service14 records
1Suhuang Zhike Capsule (苏黄止咳胶囊)
CategoryRespiratory TCM
Description

Traditional Chinese medicine capsule for treating post-cold cough and cough variant asthma, formulated with ephedra, perilla leaf and eight other herbal ingredients. It is the only recommended TCM for cough in Western medicine guidelines with clinical total effective rate over 87%.

2Irbesartan Tablets (厄贝沙坦片) - Kesu (科苏)
CategoryCardiovascular Generic Drug
Description

Antihypertensive generic medication for treating primary hypertension and diabetic nephropathy with hypertension comorbidity. Passed national consistency evaluation ensuring bioequivalence with originator brand.

3Rizatriptan Benzoate Tablets (苯甲酸利扎曲普坦片) - Haosu (豪苏)
CategoryNeurology Generic Drug
Description

Acute migraine treatment medication for adults and children aged 6-17 years, providing relief for migraine attacks with or without aura.

4Racecadotril Tablets (消旋卡多曲片) - Monika (莫尼卡)
CategoryPediatric Generic Drug
Description

Pediatric acute diarrhea medication providing rapid symptom relief through intestinal absorption regulation.

5Oseltamivir Phosphate Granules (磷酸奥司他韦颗粒)
CategoryAnti-infective Generic Drug
Description

Antiviral medication for influenza treatment and prevention, expanded production capacity at Beijing Haiyan.

6Celecoxib Capsules (塞来昔布胶囊)
CategoryAnti-inflammatory Generic Drug
Description

NSAID medication for treating osteoarthritis, rheumatoid arthritis, and acute pain, expanded production capacity at Beijing Haiyan.

7Xinsu Contrast Agent - Perfluoropropane Human Albumin Microspheres for Injection (信苏 - 注射用全氟丙烷人血白蛋白微球)
CategoryDiagnostic Imaging Agent
Description

Cardiovascular diagnostic imaging agent for enhancing cardiac ultrasound imaging, a domestic ultrasound contrast agent.

8Yiqi Tongqiao Wan (益气通窍丸)
CategoryInnovative TCM
Description

Category 1.1 traditional Chinese medicine innovative drug launched nationally, representing advancement in TCM innovation drug portfolio.

9Hydrochloride Aripiprazole Tablets (盐酸阿诺达非片)
CategoryInnovative Chemical Drug
Description

Category 1 chemical innovative drug approved for marketing, expanding the innovative drug portfolio.

10Huangqi Sports Drink (黄芪运动饮)
CategoryConsumer Health Product
Description

Sports nutrition beverage using pharmaceutical-food homology concept with organic Huangqi (Astragalus), designed for energy supplementation and physical recovery during exercise.

11Longfengtang Huangqi Essence (龙凤堂黄芪精)
CategoryConsumer Health Product
Description

Traditional Chinese medicine health product series based on Huangqi (Astragalus), flagship health brand extending from core pharmaceutical products.

12Lanqin Throat Candy/Oral Solution (蓝芩喉糖/小蓝芩口服液)
CategoryConsumer Health Product
Description

Throat care products derived from traditional Chinese medicine formulations, entering the consumer health market through convenience stores and daily consumption channels.

13Huangqi Coffee (黄芪咖啡)
CategoryConsumer Health Product
Description

Coffee product infused with Huangqi (Astragalus) extracts, combining traditional Chinese medicine ingredients with modern beverage trends, exhibited at French agricultural expo.

14Yulan Skincare Products (佑兰护肤品)
CategoryConsumer Health Product
Description

Plant-based skincare brand utilizing traditional Chinese medicine skin physiology and modern manufacturing technology.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1北京大学医学部药学院 (Peking University Health Science Center School of Pharmacy)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-23
Description

Yangzijiang Group and Beijing Haiyan co-organized a joint sports meeting with Peking University Health Science Center School of Pharmacy on October 23, 2021. The '青春闪药·扬帆起航' event included competitive sports, team building activities, and academic exchanges. The partnership aims to build relationships with pharmacy students for future talent recruitment and strengthen industry-academia ties. Joint recruitment presentations at Shenyang Pharmaceutical University are also conducted annually.

bjhaiyan.com
2北京金隅红树林环保有限公司 (Beijing BBMG Redwoods Environmental Protection Co., Ltd.)
Strategic tierMinorTypeOthers
Description

Hazardous waste disposal partner. All hazardous waste (including waste packaging materials containing chemical reagents or drugs, substandard medicines, expired drugs, waste liquids, waste chemical reagents, activated carbon, and sludge) generated by Beijing Haiyan is disposed of through this licensed hazardous waste management company, ensuring compliance with environmental regulations.

bjhaiyan.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Environmental impact assessment (EIA) agency engaged for construction projects. Conducted environmental impact assessments for new production capacity expansion (磷酸奥司他韦颗粒 and 塞来昔布胶囊) and R&D laboratory renovation projects.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major Chinese generic and specialty pharmaceutical manufacturer with strong cardiovascular and CNS franchises, deep international presence, and significant consistency evaluation/VBP participation. Comparable in cardiovascular/CNS generics and international expansion, though broader in therapeutic coverage.

2Yunnan Baiyao Group
TypeDirect peer
Description

Major Chinese TCM manufacturer that has successfully expanded into consumer health products (toothpaste, healthcare products) leveraging its TCM heritage. Highly comparable to Beijing Haiyan's TCM + large-health dual strategy.

3Livzon Pharmaceutical Group
TypeDirect peer
Description

Integrated Chinese pharmaceutical company producing both TCM preparations and chemical drug generics across digestive, cardiovascular, and oncology areas. Comparable TCM + chemical drug dual-engine business model with similar scale and therapeutic breadth.

4Guangzhou Pharmaceutical Holdings (GPHL)
TypeDirect peer
Description

Large Chinese pharma group combining TCM heritage brands (e.g. Wang Lao Ji, Banlangen) with chemical drug manufacturing and national distribution. Comparable dual TCM/chemical drug model with respiratory/cold consumer products.

5Jiangsu Hengrui Medicine
TypeBroad incumbent
Description

China's largest specialty/innovative pharmaceutical company with broad therapeutic coverage and strong R&D pipeline. Comparable as a higher-scale specialty pharma peer, but significantly larger and focused on innovative chemical drugs rather than TCM.

6China Traditional Chinese Medicine Holdings
TypeDirect peer
Description

Hong Kong-listed TCM platform consolidating multiple TCM manufacturers across respiratory, oncology-support, and chronic disease areas. Comparable as a multi-product TCM specialty pharma operator with national distribution.

7Beijing Tongrentang Group
TypeDirect peer
Description

Historic Beijing-based TCM specialist with respiratory and chronic disease franchises and a nationwide hospital/pharmacy distribution network. Directly comparable in TCM specialty pharma positioning and respiratory therapeutic area focus.

8Salubris Pharmaceuticals
TypeDirect peer
Description

Chinese specialty pharmaceutical manufacturer focused on cardiovascular and chronic disease generics with strong consistency evaluation and centralized procurement participation. Comparable to Beijing Haiyan's cardiovascular franchise (Kesu/Irbesartan) and VBP exposure.

9Shanghai Pharmaceuticals Holding
TypeBroad incumbent
Description

One of China's largest integrated pharmaceutical groups combining manufacturing, distribution, and retail pharmacy operations. Comparable in TCM + chemical drug manufacturing with national distribution, but operating at materially larger scale.

10China Resources Sanjiu Medical & Pharmaceutical
TypeDirect peer
Description

Leading Chinese TCM and OTC drug manufacturer with a respiratory/cold portfolio (e.g. 999 Ganmao Ling) and an expanding consumer health business. Closely comparable to Beijing Haiyan's TCM-led respiratory franchise plus consumer health extension.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance20 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Yangzijiang Pharmaceutical

Pharmaceutical Manufacturingbjhaiyan.com

Beijing Haiyan Pharmaceutical is the northern China R&D-manufacturing subsidiary of Yangzijiang Pharmaceutical Group, developing and producing TCM and chemical drugs (notably Suhuang Cough Capsules, Kesu Irbesartan) for distribution through the group's national hospital sales network.

What Yangzijiang Pharmaceutical does

Beijing Haiyan Pharmaceutical Co., Ltd. (扬子江药业集团北京海燕药业有限公司) is a wholly-owned subsidiary of Yangzijiang Pharmaceutical Group, established in February 2004 and headquartered on a ~99 mu (~65,979 sqm) campus in Beijing's Zhongguancun Life Science Park (Changping District). The company operates as Yangzijiang Group's only integrated R&D, manufacturing, and market expansion hub in northern China, executing a dual TCM-chemical drug ("双药并举") strategy spanning respiratory, cardiovascular, central nervous system, endocrine, and anti-infective therapeutic areas. Core marketed products include Suhuang Zhike Capsule (Suhuang Cough Capsule, the only TCM recommended in Western Medicine Cough Guidelines, entered the 2020 Chinese Pharmacopoeia), Kesu Irbesartan Tablets (antihypertensive, passed consistency evaluation), Benoic Rizatriptan Tablets (acute migraine), and Monika Racecadotril Tablets (pediatric acute diarrhea), supported by a Drug Research Institute developing additional candidates such as Xinsu ultrasound contrast agent and fat emulsion injection technology.

The subsidiary's manufacturing backbone rests on advanced pharmaceutical technology platforms, including the group's Longfentan (龙凤堂) Smart Factory for full-process digital-intelligent TCM manufacturing (automatic feeding, robot dispensing, MES systems), proprietary volatile/non-volatile fingerprint analysis methods for Suhuang (a domestic first in multi-component TCM quality control), and Box-Behnken response surface optimization for fat emulsion physical stability. Production is supported vertically through 33 standardized TCM planting bases covering 100,000 mu across China, with a dedicated Gansu base of 15,000+ mu established since 2014 and a new Longfentan industrial base launched in Gansu in 2023.

Commercially, Beijing Haiyan generates revenue through prescription pharmaceutical sales distributed exclusively via Yangzijiang Group's nationwide sales network into Chinese hospitals, pharmacies, and medical institutions, with 66 group-level products now selected in China's national volume-based procurement (集中采购) as of 2025. Pricing is governed by national reimbursement (NRDL) and centralized procurement mechanisms rather than market pricing. The group is also expanding into the "大健康" (large health) consumer segment via Huangqi Sports Drinks, Huangqi Coffee, Lanqin Throat Candy, and Yulan Skincare. Reported financials include 2018 subsidiary revenue of 991.598 million RMB with 158.68 million RMB net profit, cumulative 2004–2018 revenue of 7.418 billion RMB, and group-level 2025 international revenue growth of 425% YoY with large health segment growth of 239% YoY.

Yangzijiang Pharmaceutical firmographics

Firmographics
Name
Yangzijiang Pharmaceutical
Legal name
扬子江药业集团北京海燕药业有限公司
Website
https://bjhaiyan.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
251–500 employees
Short description
Beijing Haiyan Pharmaceutical is the northern China R&D-manufacturing subsidiary of Yangzijiang Pharmaceutical Group, developing and producing TCM and chemical drugs (notably Suhuang Cough Capsules, Kesu Irbesartan) for distribution through the group's national hospital sales network.
Ownership category
akta.pro rank

Yangzijiang Pharmaceutical industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Pharmaceutical manufacturing
  • Traditional Chinese medicine
  • Generic drug production
  • Respiratory therapeutics
  • Cardiovascular medications

Where Yangzijiang Pharmaceutical is headquartered

Location

Headquarters

HQ city
Changping
HQ country
China
HQ region
Asia

Offices1 record

Markets served

Yangzijiang Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Manufacturing and Sales: Beijing Haiyan manufactures and sells prescription pharmaceutical products including Suhuang Cough Capsules (呼吸系统), Kesu Irbesartan Tablets (心血管), Xiaoxuan Kaduoqu Tablets (儿科), and Benoic Lizatriptan Tablets (神经系统). Products are distributed through Yangzijiang Group's nationwide sales network. Revenue primarily comes from product sales to hospitals, pharmacies, and medical institutions across China.
  2. Health Consumer Products (Large Health / 大健康): Yangzijiang Group is expanding into health consumer products including Huangqi Sports Drinks, Huangqi Coffee, Lanqin Throat Candies, and Youlan Skincare products, targeting the consumer health and wellness market segment.

Pricing tiers

ModelBillingPrice
OtherOtherPrescription pharmaceutical products distributed through institutional channels — pricing governed by national medical insurance and centralized procurement systems.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Yangzijiang Pharmaceutical product offering

Product offering

Core offering

Beijing Haiyan Pharmaceutical is the northern China R&D-manufacturing-sales subsidiary of Yangzijiang Pharmaceutical Group, producing prescription pharmaceuticals across respiratory, cardiovascular, central nervous system, endocrine, and anti-infective therapeutic areas. The company combines traditional Chinese medicine (TCM) and chemical drug production, with flagship product Suhuang Zhike Capsule (TCM cough/asthma treatment) and core chemical drugs including Irbesartan Tablets, Rizatriptan Benzoate Tablets, and Racecadotril Tablets. Products are distributed through the parent group's nationwide sales network to hospitals, pharmacies, and medical institutions across China.

Product overview

Yangzijiang Pharmaceutical Group is a comprehensive pharmaceutical company with Beijing Haiyan Pharmaceutical as its northern R&D and production subsidiary. The company operates a dual strategy of traditional Chinese medicine and chemical drugs (中药、化药"双药并举"), with respiratory and cardiovascular systems as key therapeutic areas. Core products include Suhuang Zhike Capsule (entered 2020 Chinese Pharmacopoeia), Ke Su (Irbesartan Tablets), Hao Su (Rizatriptan), and Monika (Racecadotril). The company also develops health products under brands including Longfengtang, Lanqin, and Yulan, encompassing functional beverages like Huangqi Sports Drink, throat care products, and skincare. The portfolio spans from patented TCM formulas to generic chemical drugs, supported by drug research institutes conducting research across antiviral, nervous system, cardiovascular, endocrine, and respiratory areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Suhuang Zhike Capsule (苏黄止咳胶囊) Traditional Chinese medicine capsule for treating post-cold cough and cough variant asthma, formulated with ephedra, perilla leaf and eight other herbal ingredients. It is the only recommended TCM for cough in Western medicine guidelines with clinical total effective rate over 87%.
  • Irbesartan Tablets (厄贝沙坦片) - Kesu (科苏) Antihypertensive generic medication for treating primary hypertension and diabetic nephropathy with hypertension comorbidity. Passed national consistency evaluation ensuring bioequivalence with originator brand.
  • Rizatriptan Benzoate Tablets (苯甲酸利扎曲普坦片) - Haosu (豪苏) Acute migraine treatment medication for adults and children aged 6-17 years, providing relief for migraine attacks with or without aura.
  • Racecadotril Tablets (消旋卡多曲片) - Monika (莫尼卡) Pediatric acute diarrhea medication providing rapid symptom relief through intestinal absorption regulation.
  • Oseltamivir Phosphate Granules (磷酸奥司他韦颗粒) Antiviral medication for influenza treatment and prevention, expanded production capacity at Beijing Haiyan.
  • Celecoxib Capsules (塞来昔布胶囊) NSAID medication for treating osteoarthritis, rheumatoid arthritis, and acute pain, expanded production capacity at Beijing Haiyan.
  • Xinsu Contrast Agent - Perfluoropropane Human Albumin Microspheres for Injection (信苏 - 注射用全氟丙烷人血白蛋白微球) Cardiovascular diagnostic imaging agent for enhancing cardiac ultrasound imaging, a domestic ultrasound contrast agent.
  • Yiqi Tongqiao Wan (益气通窍丸) Category 1.1 traditional Chinese medicine innovative drug launched nationally, representing advancement in TCM innovation drug portfolio.
  • Hydrochloride Aripiprazole Tablets (盐酸阿诺达非片) Category 1 chemical innovative drug approved for marketing, expanding the innovative drug portfolio.
  • Huangqi Sports Drink (黄芪运动饮) Sports nutrition beverage using pharmaceutical-food homology concept with organic Huangqi (Astragalus), designed for energy supplementation and physical recovery during exercise.
  • Longfengtang Huangqi Essence (龙凤堂黄芪精) Traditional Chinese medicine health product series based on Huangqi (Astragalus), flagship health brand extending from core pharmaceutical products.
  • Lanqin Throat Candy/Oral Solution (蓝芩喉糖/小蓝芩口服液) Throat care products derived from traditional Chinese medicine formulations, entering the consumer health market through convenience stores and daily consumption channels.
  • Huangqi Coffee (黄芪咖啡) Coffee product infused with Huangqi (Astragalus) extracts, combining traditional Chinese medicine ingredients with modern beverage trends, exhibited at French agricultural expo.
  • Yulan Skincare Products (佑兰护肤品) Plant-based skincare brand utilizing traditional Chinese medicine skin physiology and modern manufacturing technology.

Quantifiable outcome

  • Suhuang Cough Capsule clinical total effective rate: 87%+
  • +5 more outcomes

Companies that use Yangzijiang Pharmaceutical

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Yangzijiang Pharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Yangzijiang Pharmaceutical partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • 北京大学医学部药学院 (Peking University Health Science Center School of Pharmacy)minorStrategic or Co-development Partner · 23 October 2021Yangzijiang Group and Beijing Haiyan co-organized a joint sports meeting with Peking University Health Science Center School of Pharmacy on October 23, 2021. The '青春闪药·扬帆起航' event included competitive sports, team building activities, and academic exchanges. The partnership aims to build relationships with pharmacy students for future talent recruitment and strengthen industry-academia ties. Joint recruitment presentations at Shenyang Pharmaceutical University are also conducted annually.
  • 北京金隅红树林环保有限公司 (Beijing BBMG Redwoods Environmental Protection Co., Ltd.)minorOthersHazardous waste disposal partner. All hazardous waste (including waste packaging materials containing chemical reagents or drugs, substandard medicines, expired drugs, waste liquids, waste chemical reagents, activated carbon, and sludge) generated by Beijing Haiyan is disposed of through this licensed hazardous waste management company, ensuring compliance with environmental regulations.
  • 中环联新(北京)环境保护有限公司 (China-EMA Joint New (Beijing) Environmental Protection Co., Ltd.)minorImplementation/ SI/ Consulting PartnerEnvironmental impact assessment (EIA) agency engaged for construction projects. Conducted environmental impact assessments for new production capacity expansion (磷酸奥司他韦颗粒 and 塞来昔布胶囊) and R&D laboratory renovation projects.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Yangzijiang Pharmaceutical competitors and assessment

Company assessment

Broad incumbents

  • Zhejiang Huahai Pharmaceutical: Major Chinese generic and specialty pharmaceutical manufacturer with strong cardiovascular and CNS franchises, deep international presence, and significant consistency evaluation/VBP participation. Comparable in cardiovascular/CNS generics and international expansion, though broader in therapeutic coverage.
  • Jiangsu Hengrui Medicine: China's largest specialty/innovative pharmaceutical company with broad therapeutic coverage and strong R&D pipeline. Comparable as a higher-scale specialty pharma peer, but significantly larger and focused on innovative chemical drugs rather than TCM.
  • Shanghai Pharmaceuticals Holding: One of China's largest integrated pharmaceutical groups combining manufacturing, distribution, and retail pharmacy operations. Comparable in TCM + chemical drug manufacturing with national distribution, but operating at materially larger scale.

Direct peers

  • Yunnan Baiyao Group: Major Chinese TCM manufacturer that has successfully expanded into consumer health products (toothpaste, healthcare products) leveraging its TCM heritage. Highly comparable to Beijing Haiyan's TCM + large-health dual strategy.
  • Livzon Pharmaceutical Group: Integrated Chinese pharmaceutical company producing both TCM preparations and chemical drug generics across digestive, cardiovascular, and oncology areas. Comparable TCM + chemical drug dual-engine business model with similar scale and therapeutic breadth.
  • Guangzhou Pharmaceutical Holdings (GPHL): Large Chinese pharma group combining TCM heritage brands (e.g. Wang Lao Ji, Banlangen) with chemical drug manufacturing and national distribution. Comparable dual TCM/chemical drug model with respiratory/cold consumer products.
  • China Traditional Chinese Medicine Holdings: Hong Kong-listed TCM platform consolidating multiple TCM manufacturers across respiratory, oncology-support, and chronic disease areas. Comparable as a multi-product TCM specialty pharma operator with national distribution.
  • Beijing Tongrentang Group: Historic Beijing-based TCM specialist with respiratory and chronic disease franchises and a nationwide hospital/pharmacy distribution network. Directly comparable in TCM specialty pharma positioning and respiratory therapeutic area focus.
  • Salubris Pharmaceuticals: Chinese specialty pharmaceutical manufacturer focused on cardiovascular and chronic disease generics with strong consistency evaluation and centralized procurement participation. Comparable to Beijing Haiyan's cardiovascular franchise (Kesu/Irbesartan) and VBP exposure.
  • China Resources Sanjiu Medical & Pharmaceutical: Leading Chinese TCM and OTC drug manufacturer with a respiratory/cold portfolio (e.g. 999 Ganmao Ling) and an expanding consumer health business. Closely comparable to Beijing Haiyan's TCM-led respiratory franchise plus consumer health extension.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Yangzijiang Pharmaceutical compliance and trust

Trust signal

Compliance20 records

Yangzijiang Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Yangzijiang Pharmaceutical leadership team

Management profile

Number of profiles

Profiles3 records

Yangzijiang Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Yangzijiang Pharmaceutical M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yangzijiang Pharmaceutical

What does Yangzijiang Pharmaceutical do?

Beijing Haiyan Pharmaceutical is the northern China R&D-manufacturing-sales subsidiary of Yangzijiang Pharmaceutical Group, producing prescription pharmaceuticals across respiratory, cardiovascular, central nervous system, endocrine, and anti-infective therapeutic areas. The company combines traditional Chinese medicine (TCM) and chemical drug production, with flagship product Suhuang Zhike Capsule (TCM cough/asthma treatment) and core chemical drugs including Irbesartan Tablets, Rizatriptan Benzoate Tablets, and Racecadotril Tablets. Products are distributed through the parent group's nationwide sales network to hospitals, pharmacies, and medical institutions across China.

Is Yangzijiang Pharmaceutical a public or private company?

Yangzijiang Pharmaceutical is a private company. It is classified as corporate owned and is currently operating.

When was Yangzijiang Pharmaceutical founded?

Yangzijiang Pharmaceutical was founded in 2004. It employs 251 to 500 people.

Where is Yangzijiang Pharmaceutical based?

Yangzijiang Pharmaceutical is headquartered in Changping, China, in the Asia region.

How does Yangzijiang Pharmaceutical make money?

Two revenue lines are on record. Pharmaceutical Manufacturing and Sales are the primary driver. The others are health Consumer Products (Large Health / 大健康).

Who are Yangzijiang Pharmaceutical's main competitors?

Broad incumbents on record are Zhejiang Huahai Pharmaceutical, Jiangsu Hengrui Medicine and Shanghai Pharmaceuticals Holding. Direct peers are Yunnan Baiyao Group, Livzon Pharmaceutical Group, Guangzhou Pharmaceutical Holdings (GPHL), China Traditional Chinese Medicine Holdings, Beijing Tongrentang Group, Salubris Pharmaceuticals and China Resources Sanjiu Medical & Pharmaceutical.

Does Yangzijiang Pharmaceutical have an API?

No public API is recorded for Yangzijiang Pharmaceutical.

What industry is Yangzijiang Pharmaceutical in?

Yangzijiang Pharmaceutical's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales